ChemoCentryx (NASDAQ:CCXI) Has $18 Target At Raymond James.

June 29, 2018 - By Cynthia Ashman

ChemoCentryx, Inc. (NASDAQ:CCXI) Corporate Logo

Big Money Sentiment decreased to 1 in Q1 2018. It has change of 0.30, from 2017Q4’s 1.3. The ratio turned negative due to ChemoCentryx, Inc. positioning: 10 sold and 36 reduced. 24 funds bought stakes and 22 increased stakes. Investors holded 23.51 million in 2017Q4 but now own 24.22 million shares or 3.03% more.

Jacobs Levy Equity owns 15,708 shs for 0% of their capital. 106,620 were accumulated by Financial Bank Of Mellon Corporation. 2,120 are held by Ameritas Investment Prtnrs. Piermont Cap holds 22,960 shs. Citigroup Inc has invested 0% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI). Moreover, Alps Advsr Inc has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 37,591 shs. Manufacturers Life Insur The holds 0% or 20,352 shs. Walleye Trading Limited Liability Corporation reported 14,400 shs. Credit Suisse Ag reported 13,269 shs. Millennium Management Ltd Limited Liability Company holds 0.01% or 324,112 shs. Spark Mngmt Ltd Liability owns 0.05% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 62,600 shs. Trexquant Investment Ltd Partnership has 11,574 shs. Metropolitan Life Insur Comm reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Amer Group has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). New York State Common Retirement Fund invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).

ChemoCentryx, Inc. registered $6.04 million net activity with 0 insider purchases and 8 insider sales since May 1, 2018. The insider Schall Thomas J. sold $2.36M. On Wednesday, May 2 KANAYA SUSAN M sold $15,709 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 1,366 shs.

What Price Target Has Raymond James Given ChemoCentryx (NASDAQ:CCXI)

Coverage of ChemoCentryx (NASDAQ:CCXI)‘s stock has begun on 28 June. Raymond James has $18 target and issued “Strong Buy” rating which means 31.29 % upside potential on CCXI stock.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Total analysts of 4 have positions in ChemoCentryx (NASDAQ:CCXI) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since March 13, 2018 according to StockzIntelligence Inc ChemoCentryx has 4 analyst reports. On Tuesday, March 13 the stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Overweight” rating by JP Morgan.

Ticker’s shares touched $13.71 during the last trading session after 1.93% change.Currently ChemoCentryx, Inc. is uptrending after 83.50% change in last June 29, 2017. CCXI has also 101,216 shares volume. CCXI outperformed the S&P 500 by 70.93%.

On August, 14 is expected ChemoCentryx, Inc. (NASDAQ:CCXI)’s earnings report, Faxor reports. earnings per share of $-0.25 is 31.58 % down from 2017’s $-0.19 EPS. After $-0.19 EPS report last quarter, Wall Street now predicts 31.58 % negative EPS growth of ChemoCentryx, Inc..

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States.The firm is worth $673.85 million. The firm targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies.The P/E ratio is 47.28. The Company’s lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor , is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

More recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were brought out by Seekingalpha.com, Benzinga.com and Finance.Yahoo.com. The first one has “InflaRx: Buy The Dip” as a title and was brought out on June 29, 2018. The next is “35 Stocks Moving In Monday’s Mid-Day Session” on June 04, 2018. And last was brought out on June 14, 2018, called “4 Top-Ranked Nasdaq Stocks That Have Doubled This Year”.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.